Abstract In a double-blind, cross-above trial, triazolam (0.25 mg) was examined in opposition to flunitrazepam (one mg) in the typical midwinter insomnia which can be generally seen among usually healthy people in Northern Norway. Every drug was offered for five evenings, in random order, having a 5-night time placebo period of time amongst the Ene